All In Biotech

Drug Trial Radar · NCT07844967

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of HS-10506

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

Jun 1, 2028

Study completion Jun 1, 2028

Sponsor

Sponsor type
Industry
First posted
Sep 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Moderate Hepatic Impairment Study Phase This phase employs a multicenter, open-label, parallel-group, single-dose study design.Two cohorts are established in this phase: Cohort A: Subjects with moderate hepatic impairment Cohort B: Subjects with normal hepatic function A total of 8 subjects of either gender will be enrolled in each cohort. Enrolled subjects will be admitted to the Phase I clinical research unit on Day -1 and fasted for at least 10 hours. On Day 1, subjects will receive a single oral dose of 20 mg HS-10506 tablets in a fasted state. Water intake is prohibited within 1 hour before and after dosing (excluding water used for drug administration). Food intake is restricted for at least 4 hours post-dose. All study medications will be administered with approximately 240 mL of water. Subjects with normal hepatic function (Cohort B) serve as the matched control group for subjects with moderate hepatic impairment (Cohort A), and shall meet the following matching criteria: The mean body mass index (BMI) of Cohort B is within ±10% of the mean BMI of Cohort A. The mean age of Cohort B is within ±3 years of the mean age of Cohort A. The number of male and female subjects in Cohort B is consistent with that in Cohort A for each gender. Mild Hepatic Impairment Study Phase Based on the results of the moderate hepatic impairment study phase, the sponsor and principal investigator will jointly determine whether to conduct a study to evaluate the effect of mild hepatic impairment. The phase design and procedures of the mild hepatic impairment are consistent with those of the moderate hepatic impairment. Subjects with normal hepatic function (Cohort D) serve as the matched control group for subjects with mild hepatic impairment (Cohort C), and shall meet the following matching criteria: The mean BMI of Cohort D is within ±10% of the mean BMI of Cohort C. The mean age of Cohort D is within ±3 years of the mean age of Cohort C. The number of male and female subjects in Cohort D is consistent with that in Cohort C for each gender.

Conditions

  • Hepatic Impairment (Moderate or Mild) & Normal Hepatic Function

Interventions

  • HS-10506Drug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK parameter of HS-10506: CmaxTime frame: Day 1 pre-dose to 120 hours post-dose
  2. PK parameter of HS-10506: AUC0-tTime frame: Day 1 pre-dose to 120 hours post-dose
  3. PK parameter of HS-10506: AUC0-∞Time frame: Day 1 pre-dose to 120 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • No. 121, Wanshui Road, Hefei High-tech Zone

    Hefei, Anhui, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.